@article{e63476858b194723bafc7757b96c9a80,
title = "ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)",
author = "Ma, {Patrick C.}",
note = "Funding Information: uniform disclosure form (available at http://dx.doi. org/10.21037/pcm-2020-mnsclc-10). The series “Evidence and Controversies in the treatment of metastatic NSCLC” was commissioned by the editorial office without any funding or sponsorship. The author has the following potential conflicts of interest to declare. Dr. Ma reports grants and personal fees from Merck, grants and personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, grants and personal fees from Apollomics, grants from LOXO, grants from Medimmune, grants from",
year = "2021",
month = mar,
doi = "10.21037/pcm-2020-mnsclc-10",
language = "English (US)",
volume = "4",
journal = "Precision Cancer Medicine",
issn = "2617-2216",
publisher = "AME Publishing Company",
number = "March",
}
